|
PHF13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62535999999047E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.409990E-04 |
| Normal-vs-Stage2 |
1.030640E-01 |
| Normal-vs-Stage3 |
1.81961999999869E-05 |
| Normal-vs-Stage4 |
1.24450000305032E-08 |
| Stage1-vs-Stage2 |
6.987800E-02 |
| Stage1-vs-Stage3 |
5.473200E-01 |
| Stage1-vs-Stage4 |
1.938050E-03 |
| Stage2-vs-Stage3 |
2.235900E-02 |
| Stage2-vs-Stage4 |
7.52729999999868E-05 |
| Stage3-vs-Stage4 |
6.056700E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63620000004361E-06 |
| Normal-vs-AfricanAmerican |
2.766900E-04 |
| Normal-vs-Asian |
8.07680000000088E-05 |
| Caucasian-vs-AfricanAmerican |
3.168000E-01 |
| Caucasian-vs-Asian |
6.953800E-01 |
| AfricanAmerican-vs-Asian |
5.493600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.167730E-04 |
| Normal-vs-Female |
1.76839000000095E-05 |
| Male-vs-Female |
7.982600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.58160000000218E-05 |
| Normal-vs-Age(41-60Yrs) |
9.79890000000205E-05 |
| Normal-vs-Age(61-80Yrs) |
1.192730E-04 |
| Normal-vs-Age(81-100Yrs) |
2.742000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.379600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.456800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.150600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.448200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.559400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.608000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.883800E-01 |
| Classical-VS-Follicular |
5.78426195829707E-14 |
| Classical-VS-Other |
4.130600E-01 |
| Classical-VS-Normal |
8.82249995282081E-09 |
| Tall-VS-Follicular |
1.24649999988513E-07 |
| Tall-VS-Other |
2.878400E-01 |
| Tall-VS-Normal |
4.11349999995814E-06 |
| Follicular-VS-Other |
6.584300E-02 |
| Follicular-VS-Normal |
7.886800E-01 |
| Other-VS-Normal |
1.095560E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.066230E-02 |
| Normal-vs-N1 |
3.80389999999897E-05 |
| N0-vs-N1 |
3.276300E-03 |
|
|
